Trials / Completed
CompletedNCT00035945
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS 14803 |
Timeline
- Start date
- 2001-10-01
- Primary completion
- 2004-05-01
- Completion
- 2004-05-01
- First posted
- 2002-05-08
- Last updated
- 2022-12-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00035945. Inclusion in this directory is not an endorsement.